Qian Jin, Tang Qinglin, Cronin Bart, Markovich Robert, Rustum Abu
Global Quality Services-Analytical Sciences, Schering-Plough, 1011 Morris Avenue, Union, NJ 07083, USA.
J Chromatogr A. 2008 Jun 13;1194(1):48-56. doi: 10.1016/j.chroma.2008.01.040. Epub 2008 Jan 20.
Intron Powder for Injection is a lyophilized formulation of Interferon alfa-2b marketed for treatment of Hepatitis C and some cancer indications. Human Serum Albumin (HSA) is used as a lyoprotectant and cryoprotectant at 1.0 mg/mL in the product formulation. No stability-indicating method, which can quantitate HSA and its dimer or oligomer aggregates in the formulated product, has been published to date. This paper describes the development and validation of a stability-indicating high performance size exclusion chromatography (HPSEC) method for the assay of HSA and estimation of HSA related compounds in lyophilized Intron Powder for Injection. The method employs a YMC-Pack Diol-200 column (7.8 mm x 30 cm, 5 microm porous particles with 250 A pore size), UV detection at 214 nm, and a mobile phase of 0.1 M phosphate buffer at pH 7.0 with 0.1 M sodium sulfate. The mobiles phase runs in an isocratic mode at 1.0 mL/min and the total chromatographic run time is 30 min. The method was validated for specific, linearity, accuracy, sensitivity, and robustness. It was shown to be specific for HSA and HSA aggregates (dimer and oligomers) with a limit of quantitation of 0.0005 mg/mL or 0.05% of HSA label claim in the presence of active therapeutic protein, Interferon alfa-2b, and the other pharmaceutical excipients, glycine, sodium phosphate dibasic, sodium phosphate monobasic. The method is stability indicating and is suitable for assay of HSA from 0.0005 mg/mL to 1.5mg/mL. (0.05-150% of HSA label claim) and for estimation of HSA related aggregates (dimer, and oligomer) from 0.0005 mg/mL to 0.15 mg/mL (0.05-15% of HSA label claim). The method is robust for routine use in product quality control. The method was applied to the analysis of batches of lyophilized Intron Powder for Injection of low, middle and high strength from the beginning, middle and end of shelf-life. The results indicated that HSA is stable in the product through out its shelf-life.
注射用干扰素α-2b冻干制剂用于治疗丙型肝炎和某些癌症适应症。在产品配方中,人血清白蛋白(HSA)以1.0 mg/mL用作冻干保护剂和低温保护剂。迄今为止,尚未发表能够定量制剂产品中HSA及其二聚体或寡聚体聚集体的稳定性指示方法。本文描述了一种用于测定注射用冻干干扰素粉中HSA并估算HSA相关化合物的稳定性指示高效体积排阻色谱(HPSEC)方法的开发和验证。该方法采用YMC-Pack Diol-200柱(7.8 mm×30 cm,5微米多孔颗粒,孔径250 Å),在214 nm处进行紫外检测,流动相为pH 7.0的0.1 M磷酸盐缓冲液和0.1 M硫酸钠。流动相以1.0 mL/min的等度模式运行,总色谱运行时间为30分钟。该方法在特异性、线性、准确性、灵敏度和稳健性方面进行了验证。结果表明,在活性治疗蛋白干扰素α-2b以及其他药用辅料甘氨酸、磷酸氢二钠、磷酸二氢钠存在的情况下,该方法对HSA和HSA聚集体(二聚体和寡聚体)具有特异性,定量限为0.0005 mg/mL或HSA标签声明量的0.05%。该方法具有稳定性指示作用,适用于测定浓度为0.0005 mg/mL至1.5mg/mL(HSA标签声明量的0.05 - 150%)的HSA,以及估算浓度为0.0005 mg/mL至0.15 mg/mL(HSA标签声明量的0.05 - 15%)的HSA相关聚集体(二聚体和寡聚体)。该方法在产品质量控制的常规使用中具有稳健性。该方法应用于分析有效期开始、中间和结束时低、中、高强度批次的注射用冻干干扰素粉。结果表明,在产品的整个有效期内HSA是稳定的。